Skip to main content

PRLB Q2 Deep Dive: CNC Machining Growth Offsets Margin Pressure, New CEO Prioritizes Execution

PRLB Cover Image

Manufacturing services provider Proto Labs (NYSE: PRLB) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.5% year on year to $135.1 million. On top of that, next quarter’s revenue guidance ($134 million at the midpoint) was surprisingly good and 3.1% above what analysts were expecting. Its non-GAAP profit of $0.41 per share was 19.9% above analysts’ consensus estimates.

Is now the time to buy PRLB? Find out in our full research report (it’s free).

Proto Labs (PRLB) Q2 CY2025 Highlights:

  • Revenue: $135.1 million vs analyst estimates of $128.1 million (7.5% year-on-year growth, 5.4% beat)
  • Adjusted EPS: $0.41 vs analyst estimates of $0.34 (19.9% beat)
  • Adjusted EBITDA: $19.69 million vs analyst estimates of $17.74 million (14.6% margin, 11% beat)
  • Revenue Guidance for Q3 CY2025 is $134 million at the midpoint, above analyst estimates of $130 million
  • Adjusted EPS guidance for Q3 CY2025 is $0.39 at the midpoint, above analyst estimates of $0.37
  • Operating Margin: 3.7%, down from 4.8% in the same quarter last year
  • Market Capitalization: $1.14 billion

StockStory’s Take

Proto Labs delivered second quarter results that surpassed Wall Street expectations, driven by robust demand in its core manufacturing services. Management highlighted record revenue fueled by strong growth in CNC machining, especially from aerospace and defense customers, as a key contributor to the outperformance. CEO Suresh Krishna, newly appointed in the role, emphasized that investments in marketing and sales enablement were successful in expanding relationships with strategic accounts. Krishna also noted that the company’s strategy of increasing customer engagement across both its digital factories and partner network is showing traction. "We have a very innovative and resilient culture and a pervasive mindset for continuous improvement," Krishna shared, adding that expanding share of wallet with larger accounts remains a top priority.

Looking forward, Proto Labs’ guidance is underpinned by continued momentum in its CNC machining segment and efforts to improve customer experience across its platforms. Management believes the combination of a diversified manufacturing footprint and investments in digital fulfillment will help the company navigate evolving trade policies and margin headwinds from tariffs. CEO Krishna stated, “My immediate focus is to listen, learn and engage closely with our teams, customers and partners to identify the highest impact opportunities.” Management also pointed to the recent ISO certification of its U.S. metal 3D printing facility as a potential growth lever in medical device manufacturing, while cautioning that near-term margin pressures from tariffs and shifting product mix may persist.

Key Insights from Management’s Remarks

Management attributed the quarter’s outperformance to CNC machining strength, expanded customer relationships, and improvements in sales execution, while addressing tariff-driven margin pressures.

  • CNC machining demand surge: Proto Labs saw record growth in CNC machining, attributed to heightened orders from aerospace and defense clients. Factory and network channels both contributed, with U.S. CNC revenue up 30% year-over-year, reflecting customer preference for rapid, high-requirement parts.

  • Strategic account expansion: The company reported an 11% increase in revenue per customer and a 44% rise in customers using both its factory and network platforms. Management credited targeted marketing and go-to-market reorganization for this growth, particularly with larger accounts.

  • Tariff-driven margin headwinds: Margins were pressured by U.S. tariffs on aluminum and steel, especially in the network business, due to lead time lags in adjusting prices. CFO Daniel Schumacher explained that while the company absorbs short-term costs to maintain customer relationships, pricing adjustments have now restored margins to pre-tariff levels.

  • Medical device quality milestone: The Raleigh, North Carolina facility received ISO 13485 certification for metal 3D printing, a key requirement for medical device manufacturing. Management sees this as a catalyst for growth in medical and implantable device markets.

  • European market softness: Revenue in Europe declined 15% as manufacturing activity contracted. Management reorganized its European teams and continues to seek ways to reignite demand, but acknowledged ongoing economic headwinds in the region.

Drivers of Future Performance

Proto Labs expects momentum in core U.S. markets and strategic segments, but acknowledges ongoing margin and geographic challenges.

  • Continued CNC and aerospace strength: Management expects sustained demand from aerospace and defense customers to support top-line growth, especially in CNC machining. The company is also targeting increased share of wallet with production-focused accounts, aiming to balance both prototyping and long-run manufacturing.

  • Margin recovery initiatives: The company is actively refining its AI-driven pricing algorithms and fulfillment network to better absorb future tariff changes and optimize manufacturing costs. Management believes these actions will help restore operating margins closer to historical levels, but cautions that product mix and external trade policies remain unpredictable.

  • European market uncertainty: Management remains cautious on Europe, citing persistent contraction in manufacturing activity. While internal reorganization efforts are underway, the company does not expect a rapid recovery and is focused on stabilizing its regional base before pursuing aggressive expansion.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be monitoring (1) sustained momentum in CNC machining, particularly from aerospace and defense customers; (2) stabilization of operating margins as tariff pricing adjustments take full effect; and (3) progress in reigniting European demand through go-to-market changes. Additional developments in medical device manufacturing, following ISO certification, will also be important signposts for future growth.

Proto Labs currently trades at $47.65, up from $39.11 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.